Sign in

Recombinant human insulin

1982Big moment

Humulin, human insulin made by engineered bacteria, becomes the first approved drug produced with recombinant DNA.

The story

In October 1982 the U.S. Food and Drug Administration approved Humulin, human insulin produced by genetically engineered bacteria, for sale by Eli Lilly. It was the first approved medicine made with recombinant DNA technology, in which a gene is moved from one organism into another so the host produces a useful protein.

Insulin had saved lives since 1921, when Frederick Banting, Charles Best, James Collip and John Macleod showed that extracts of pancreas could treat diabetes. For decades all insulin came from the pancreases of cattle and pigs collected at slaughterhouses. It took many thousands of pounds of animal pancreas to make a single pound of insulin, and supply depended on the meat industry, raising fears of shortages as diabetes became more common. Animal insulin also differs slightly from the human form, and some patients developed allergic reactions or immune responses to it. Meanwhile, in 1973 Stanley Cohen and Herbert Boyer had shown that genes could be cut and spliced into bacteria, and in 1976 Boyer and the investor Robert Swanson founded Genentech to use the technique.

In 1978 Genentech scientists, including David Goeddel, made human insulin in Escherichia coli by growing the two protein chains separately in bacteria and joining them, a race that included academic labs at Harvard and the University of California. Genentech licensed the process to Lilly, which had the manufacturing capacity and diabetes market. Lilly's Humulin reached pharmacies in 1982 and proved that bacteria could be factories for human proteins. It began the biotechnology drug industry. Later 'designer' insulins, starting with insulin lispro in 1996, altered the molecule to act faster or slower.

Why it mattered

  • Biotechnology became a pharmaceutical industry, with engineered proteins such as growth hormone, clotting factors and antibodies following Humulin.
  • Diabetes patients gained a reliable supply of pure human insulin that no longer depended on slaughterhouse tissue.
  • Genentech's success, and its soaring 1980 stock offering, drew investment into the sector.
  • Designer insulin analogs, which act faster or longer than natural insulin, became possible by modifying the gene.

Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made

Community notes

Loading notes…

Learn more ranked by votes

BookSally Smith Hughes
Genentech: The Beginnings of Biotech
Search Open Library
VideoSearch YouTube
first recombinant insulin Genentech
Search YouTube